^
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
Cancer Discov - 1 week
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
Cancer Discov - 1 week
miR-142 overexpression
Ovarian Cancer
bevacizumab
Sensitive: C3 – Early Trials
J Ovarian Res - 1 week
miR-25 underexpression
Ovarian Cancer
bevacizumab
Sensitive: C3 – Early Trials
J Ovarian Res - 1 week
TP53 mutation
Ovarian Cancer
modafinil
Sensitive: C3 – Early Trials
Cancer Gene Ther - 2 weeks
TP53 mutation
Ovarian Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Gene Ther - 2 weeks
AR positive
Ovarian Cancer
enzalutamide
Sensitive: C3 – Early Trials
Gynecol Oncol - 3 weeks
MUC1 expression
Ovarian Cancer
P-MUC1C-ALLO1
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
VTCN1 expression
Ovarian Cancer
SGN-B7H4V
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
HRD
Ovarian Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
BRCA1 mutation
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
BRCA1 mutation
Ovarian Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
BRCA2 mutation
Ovarian Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
topotecan
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
bevacizumab
Sensitive: A1 - Approval
BRCA1 mutation
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
BRCA2 mutation
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
trabectedin
Sensitive: A1 - Approval
HRD
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
Ovarian Cancer
pamiparib
Sensitive: A1 - Approval
BRCA1 mutation
Ovarian Cancer
pamiparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
leucovorin calcium
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
leuprolide acetate
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
exemestane
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
cisplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
pemetrexed
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
melphalan
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
irinotecan
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
trametinib
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
fulvestrant
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
sorafenib
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
tamoxifen
Sensitive: A2 - Guideline
BRCA1 mutation
Ovarian Cancer
bevacizumab
Resistant: A2 - Guideline
BRCA2 mutation
Ovarian Cancer
bevacizumab
Resistant: A2 - Guideline
MSI-H/dMMR
Ovarian Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
megestrol
Sensitive: A2 - Guideline
NTRK1 fusion
Ovarian Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Ovarian Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Ovarian Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Ovarian Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Ovarian Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Ovarian Cancer
entrectinib
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
letrozole
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
anastrozole
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
pazopanib
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
carboplatin + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
CaT
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
CP
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
EP
Sensitive: A2 - Guideline
TMB-H
Ovarian Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
BEP
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
VAC
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
cisplatin + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
olaparib + bevacizumab
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
bevacizumab + niraparib
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Ovarian Cancer
IMGN 853
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
trabectedin
Sensitive: B - Late Trials
BRCA1 mutation
Ovarian Cancer
olaparib + cediranib
Sensitive: B - Late Trials
HRD
Ovarian Cancer
olaparib
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
olaparib + cediranib
Sensitive: B - Late Trials
PD-L1 expression
Ovarian Cancer
bevacizumab + atezolizumab
Resistant: B - Late Trials
BRCA1 mutation
Ovarian Cancer
trabectedin
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
PARP inhibitor
Sensitive: B - Late Trials
BRCA1 mutation
Ovarian Cancer
PARP inhibitor
Sensitive: B - Late Trials
No biomarker
Ovarian Cancer
OMP-305B83
Sensitive: B - Late Trials
BRCA1 mutation
Ovarian Cancer
ABT-888
Sensitive: B - Late Trials
BRCA1 mutation
Ovarian Cancer
fluzoparib
Sensitive: B - Late Trials
HRD
Ovarian Cancer
rucaparib
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
fluzoparib
Sensitive: B - Late Trials
RAD51D mutation
Ovarian Cancer
rucaparib
Sensitive: B - Late Trials
RAD51C mutation
Ovarian Cancer
rucaparib
Sensitive: B - Late Trials
HRD
Ovarian Cancer
ABT-888
Sensitive: B - Late Trials
TTC39B rs7874043
Ovarian Cancer
carboplatin + paclitaxel
Sensitive: B - Late Trials
TTC39B rs72700653
Ovarian Cancer
carboplatin + paclitaxel
Sensitive: B - Late Trials
PSIP1 overexpression
Ovarian Cancer
carboplatin + paclitaxel
Resistant: B - Late Trials